Marché de l'héparine en Amérique du Nord - Tendances et prévisions de l'industrie jusqu'en 2028

Analyse et perspectives du marché : marché nord-américain de l'héparine

Le marché nord-américain de l'héparine devrait connaître une croissance exponentielle au cours de la période de prévision 2021-2028. Data Bridge Market Research analyse le marché pour s'attendre à une croissance à un TCAC de 6,3 % au cours de la période de prévision mentionnée ci-dessus.

L'héparine est un médicament qui prévient et traite les caillots sanguins. C'est un médicament utilisé pour traiter les anomalies de la coagulation sanguine. Elle est également utilisée pour empêcher le sang de coaguler après une intervention chirurgicale, pendant les transfusions sanguines, la dialyse et pendant les prélèvements sanguins. En libérant une protéine anticoagulante, elle favorise la fluidité de la circulation sanguine. On l'appelle anticoagulant. On traite toutes ces maladies par la coagulation intravasculaire disséminée, la thrombose veineuse profonde, l'embolie pulmonaire et la thromboembolie artérielle. Elle n'élimine pas les caillots sanguins ; au contraire, elle les empêche de grossir et de créer des complications plus catastrophiques. L'héparine est une substance qui provient des tissus muqueux des animaux d'élevage abattus.

L'augmentation de la thromboembolie veineuse et des maladies cardiovasculaires est le principal facteur influençant le taux de croissance du marché. En outre, l'augmentation du nombre d'applications de l'héparine dans diverses interventions chirurgicales, notamment orthopédiques et cardiaques, le soutien croissant du gouvernement à l'amélioration des infrastructures de santé et l'augmentation de la demande de chirurgies en raison de l'augmentation de la population gériatrique sont les facteurs qui vont développer le marché de l'héparine. En outre, la présence de mimétiques d'héparine synthétiques et semi-synthétiques qui sont utiles dans le traitement de la coagulation, du cancer et des troubles inflammatoires amortira le taux de croissance du marché.

De plus, l’augmentation des activités de recherche et développement et l’utilisation croissante d’étiquettes accrocheuses pour prévenir les blessures par piqûre d’aiguille offriront des opportunités bénéfiques pour le marché de l’héparine au cours de la période de prévision 2021-2028.

However, high cost of healthcare and side effects associated with heparin are the factors that will hinder the market growth. Also, the presence of alternative anticoagulants will further challenge the heparin market in the forecast period mentioned above.

This North America heparin market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the North America heparin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

North America Heparin Market Scope and Market Size

North America heparin market is segmented on the basis of product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of product type, the heparin market is segmented into unfractionated heparin, low molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH).
• On the basis of mode of administration, the heparin market is segmented into oral and parenteral.
• On the basis of source, the heparin market is segmented into bovine and porcine.
• On the basis of ingredients, the heparin market is segmented into sodium, calcium and others.
• On the basis of availability, the heparin market is segmented into raw and processed.
• On the basis of treatment, the heparin market is segmented into deep vein thrombosis, pulmonary embolism, arterial thromboembolism and others.
• On the basis of application, the heparin market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis, diagnostic tests and others.
• On the basis of therapeutics, the heparin market is segmented into cardiovascular, respiratory, oncology, nephrology, CNS and others.
• On the basis of strength, the heparin market is segmented into 10 unit, 100 unit, 1000 unit, 5000 unit, 10000 unit, 25000 unit and others.
• On the basis of type, the heparin market is segmented into generics and brands.
• On the basis of container, the heparin market is segmented into bottles, bags, vials and others.
• On the basis of packaging, the heparin market is segmented into glass and plastic.
• On the basis of end-users, the heparin market is segmented into hospital, clinics, homecare, ambulatory surgical centres and others.
• The heparin market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and drug store, online pharmacy and others.

North America Heparin Market Country Level Analysis

North America heparin market is segmented on the basis of product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end-users and distribution channel.

The countries covered in North America heparin market report are the U.S., Canada and Mexico.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

North America heparin market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and North America Heparin Market Share Analysis

North America heparin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to North America heparin market research.

Français Les principaux acteurs couverts dans le rapport sur le marché de l'héparine en Amérique du Nord sont F. Hoffmann-La Roche Ltd., Mylan NV, Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Aspen Holdings, Changzhaou Qianhong Bio-pharma Co., ltd., Eisai Co., Ltd., Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, LEO Pharma A/S, Novartis AG, SARIA A/S GmbH & Co. KG, OPOCRIN SPA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Dr. Reddy's Laboratories Ltd., B. Braun Melsungen AG, Baxter, entre autres. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.

SKU-43608